Filing Details

Accession Number:
0000950170-24-070991
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-06-07 19:18:17
Reporting Period:
2024-06-05
Accepted Time:
2024-06-07 19:18:17
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1503802 Karyopharm Therapeutics Inc. KPTI () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1270734 Deepika Pakianathan C/O Delphi Ventures,
63 Bovet Road, Suite 351
San Mateo CA 94402
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2024-06-05 463,518 $0.96 346,615 No 4 S Indirect See footnote
Common Stock Disposition 2024-06-05 4,526 $0.96 3,385 No 4 S Indirect See footnote
Common Stock Disposition 2024-06-06 117,307 $0.98 229,308 No 4 S Indirect See footnote
Common Stock Disposition 2024-06-06 1,145 $0.98 2,240 No 4 S Indirect See footnote
Common Stock Disposition 2024-06-07 229,308 $0.95 0 No 4 S Indirect See footnote
Common Stock Disposition 2024-06-07 2,240 $0.95 0 No 4 S Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
Footnotes
  1. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.899 to $0.989, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
  2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.97 to $1.0302, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.9303 to $0.965, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
  4. The shares are held directly by Delphi Ventures VIII, L.P. ("DV VIII"). Delphi Management Partners VIII, L.L.C. ("DMP VIII"), is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.
  5. The shares are held directly by Delphi BioInvestments VIII, L.P. ("DB VIII"). DMP VIII is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.